Business
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
The positive results from this preclinical study underscore Ketamir-2's potential as a superior alternative to traditional ketamine Unlike ketamine, which
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"The positive results from this preclinical study underscore Ketamir-2's potential as a superior alternative to traditional ketamine\nUnlike ketamine, which requires intravenous or intranasal administration, Ketamir-2's oral formulation promises ease of use and better patient compliance and is not a controlled substance under DEA rules\nMIAMI, June 10, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (\"MIRA\" or the \"Company\"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced positive preclinical study results highlighting the potential efficacy and safety profile of Ketamir-2, MIRA's novel oral ketamine analog designed to treat depression and treatment-resistant depression (TRD).\n\nMira Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2The highly encouraging study results further MIRA's goal of submitting an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) later this year which, if granted, would allow for human clinical trials of Ketamir-2.\nKey Findings from the Study\nThe study, conducted by Pharmaseed Ltd., evaluated the anti-depressive and anxiolytic effects of oral Ketamir-2, in comparison with oral ketamine, using established behavioral tests in male mice. The tests included the Open Field Test (OFT), Elevated Plus Maze (EPM), and Forced Swim Test (FST). Under the experimental conditions of these studies, it was possible to use 10 fold-higher oral doses of Ketamir-2, compared with ketamine, which induced major sedative and other side effects already at low doses.\nThe following findings were observed:\nOpen Field Test (OFT)Mice treated with Ketamir-2 showed dose-related, significantly greater locomotor activity, higher travel speed and a trend towards an increased time spent in the center of the arena, indicating reduced anxiety levels.Elevated Plus Maze (EPM)In this model of depression, significant increases in travel distance and speed were observed in mice treated with Ketamir-2. Furthermore, Ketamir-2 treated mice spent more time in the open arms of the maze, suggesting reduced anxiety.Forced Swim Test (FST)In this model of depression and anxiety, mice in the Ketamir-2 treated arm demonstrated reduced swimming distances and speed, indicatin...